➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Dow
Harvard Business School
Johnson and Johnson
AstraZeneca

Last Updated: September 17, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for LY2157299


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug LY2157299?

LY2157299 is an investigational drug.

There have been 23 clinical trials for LY2157299. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2014.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Hepatocellular, and Pancreatic Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, Fundación para la Investigación del Hospital Clínico de Valencia, and Bristol-Myers Squibb.

There are seventy-four US patents protecting this investigational drug and eight hundred and fifty-one international patents.

Recent Clinical Trials for LY2157299
TitleSponsorPhase
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAgendiaPhase 1/Phase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerAzienda Ospedaliera Niguarda Cà GrandaPhase 1/Phase 2
Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerCatalan Institute of HealthPhase 1/Phase 2

See all LY2157299 clinical trials

Clinical Trial Summary for LY2157299

Top disease conditions for LY2157299
Top clinical trial sponsors for LY2157299

See all LY2157299 clinical trials

US Patents for LY2157299

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY2157299 ⤷  Try it Free Determination of TGF-.beta. pathway activity using unique combination of target genes KONINKLIJKE PHILIPS N.V. (Eindhoven, NL) ⤷  Try it Free
LY2157299 ⤷  Try it Free Compositions comprising bacterial strains 4D Pharma Research Limited (GB) ⤷  Try it Free
LY2157299 ⤷  Try it Free Compositions comprising bacterial strains 4D Pharma Research Limited (Aberdeen, GB) ⤷  Try it Free
LY2157299 ⤷  Try it Free Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) ⤷  Try it Free
LY2157299 ⤷  Try it Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Try it Free
LY2157299 ⤷  Try it Free Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LY2157299

Drugname Country Document Number Estimated Expiration Related US Patent
LY2157299 Australia AU2015334840 2034-10-24 ⤷  Try it Free
LY2157299 Brazil BR112017007965 2034-10-24 ⤷  Try it Free
LY2157299 Canada CA2965442 2034-10-24 ⤷  Try it Free
LY2157299 China CN107077536 2034-10-24 ⤷  Try it Free
LY2157299 Denmark DK3210142 2034-10-24 ⤷  Try it Free
LY2157299 European Patent Office EP3210142 2034-10-24 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Dow
Colorcon
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.